Hubei Jumpcan Pharmaceutical (600566) H2 2025 earnings summary

Executive summary

• Revenue for 2025 was RMB 6.22 billion, down 22.43% year-over-year; net profit attributable to shareholders was RMB 1.78 billion, down 29.77%.

• Decline driven by lower sales of core products and impact of centralized procurement policies.

• Company advanced R&D, launched new products, and strengthened digital and quality management.

• Maintained strong market positions in pediatric and anti-inflammatory TCM segments.

Financial highlights

• Operating income: RMB 6.22 billion, down 22.43% year-over-year.

• Net profit attributable to shareholders: RMB 1.78 billion, down 29.77% year-over-year.

• Operating cash flow: RMB 1.20 billion, down 44.94% year-over-year.

• Basic and diluted EPS: RMB 1.93, down 30.07% year-over-year.

• Gross margin remained high at 79.15%.

Outlook and guidance

• 2026 focus: accelerate innovative drug launches, consolidate core product market share, and deepen retail and hospital channel integration.

• Continued investment in R&D and digital transformation to drive long-term growth.